Dallas, TX (PRWEB) June 28, 2013
A MDL Statistics Report issued on May 14th by the U.S. Judicial Panel on Multidistrict Litigation (JPML) claims that at least 161 Fresenius GranuFlo lawsuit cases have been filed in federal litigation in the district of Massachusetts since March. (IN RE: FRESENIUS GRANUFLO/NATURALYTE DIALYSATE LITIGATION, MDL NO. 2428)
“Individuals who have allegedly suffered serious injuries including cardiac arrest and heart attacks from these products continue to contact us,” said Russell Budd, founder and managing shareholder of Baron and Budd, a national plaintiff’s law firm handling GranuFlo lawsuit cases. “At this time we have begun offering free GranuFlo lawsuit evaluations to these dialysis patients and their loved ones. As GranuFlo was a widely used dialysis product, we expect the number of GranuFlo lawsuit cases to continue to increase.”
Both GranuFlo and NaturaLyte were discussed in an “Urgent Product Notification” sent by the dialysis drug’s manufacturer Fresenius Medical Care to its customer clinics in March of 2012 that mentioned possible heart risks associated with GranuFlo and NaturaLyte use. The U.S. Food and Drug Administration (FDA) took notice of the notification several months later and issued a Class 1 GranuFlo recall, a classification that is only issued when a medical product has a significant risk of serious injury or death. (http://www.fda.gov/MedicalDevices/Safety/ListofRecalls/ucm309990.htm; FDA, March 29, 2013)
According to court documents, GranuFlo lawsuit litigation was established by an order of the JPMB on March 29th. At the time, 11 Fresenius GranuFlo lawsuit cases were transferred to the proceeding. In these GranuFlo lawsuit cases, plaintiffs allege that Fresenius Medical Care was aware of the serious heart risks associated with their products, GranuFlo and NaturaLyte, and failed to sufficiently warn patients and doctors regarding the full scope of the risks.
In compliance with GranuFlo lawsuit litigation, dialysis patients who allegedly suffered serious heart injuries from GranuFlo and NaturaLyte use, including sudden heart attacks and sudden cardiac death, within 48 hours of dialysis treatment may have the opportunity to file a GranuFlo lawsuit against manufacturer Fresenius to receive compensation for lost wages, pain and suffering and medical expenses. To learn more about the GranuFlo lawsuit visit Baron and Budd’s website http://baronandbudd.com/areas-of-practice/pharmaceuticals/granuflo-lawyer/ or call Baron and Budd’s Chief GranuFlo lawyer at 1.866.844.4556.
If you or someone you know has undergone dialysis treatments using the GranuFlo or NaturaLyte dialysis drug and suffered severe health injuries, contact Baron and Budd’s chief GranuFlo lawyer today at 1.866.855.4556 or email our chief GranuFlo lawyer at info (at) baronbudd (dot) com.
Baron and Budd has a well-established record of success protecting the rights of people against large, negligent corporations, including pharmaceutical companies, for over 35 years. Recently, Baron and Budd lawyers were involved in litigation surrounding the diabetes drug Avandia. Baron and Budd represented over 7,000 patients allegedly harmed by Avandia use, and currently represents numerous states in lawsuits against the manufacturer GlaxoSmithKline (In Re: Avandia Marketing, Sales Practices and Products Liability Litigation, MDL No. 1871, E.D. Pa.). In the 1990s, Baron and Budd was closely involved in litigation surrounding the then-popular diet drug Fen-Phen. The resulting settlement was valued at over $1.275 billion (In re Diet Drugs (Phentermine | Fenfluramine | Dexfenfluramine) Products Liability Litigation, Case No. 98- MDL No. 1203 (E.D. Pa.).
About Baron & Budd
With offices in Dallas, Baton Rouge, Austin and Los Angeles, the law firm Baron Budd is nationally recognized with over 35 years of “Protecting What’s Right” for people, communities and businesses harmed by negligence. Baron & Budd’s size and resources enable the firm to take on large and complex cases. The firm represents individuals, governmental and business entities in areas as diverse as water contamination, Gulf oil spill, Qui Tam, California Proposition 65 violations, unsafe drugs and medical devices, Chinese drywall, deceptive advertising, consumer financial fraud, securities fraud and asbestos cancers such as mesothelioma.